ATEMPT 2.0: Adjuvant T-DM1 vs TH
Eligible age
18+ yrs
Accepts
All genders
Locations
15 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Sponsor: Dana-Farber Cancer Institute
You may qualify if…
- ✓ Patients must have HER2-positive Stage I histologically confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or micrometastases (N1mic) breast cancer according to the AJCC 8th edition anatomic staging table.
- ✓ If the patient has had a negative sentinel node biopsy, then no further axillary dissection is required, and the patient is determined to be node-negative. If an axillary dissection without sentinel lymph node biopsy is performed to determine nodal status, at least six axillary lymph nodes must be removed and analyzed, and determined to be negative, for the patient to be considered node-negative. Axillary nodes with single cells or tumor clusters ≤ 0.2 mm by either H\&E or immunohistochemistry (IHC) will be considered node-negative.
- ✓ Any axillary lymph node with tumor clusters between 0.02 and 0.2 cm is considered a micrometastasis. Patients with a micrometastasis are eligible. An axillary dissection is not required to be performed in patients with a micrometastasis found by sentinel node evaluation. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the principal investigator will make the final determination as to eligibility. The investigator must document approval in the patient medical record.
- ✓ Patients who have an area of a T1aN0, ER+ (defined as \>10%), HER2-negative cancer in addition to their primary HER2-positive tumor are eligible.
- ✓ HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing. NOTE: HER-2 status must be confirmed to be positive by central review by NeoGenomics prior to patient starting protocol therapy. Patients previously having had HER2 immunohistochemical testing by NeoGenomics do not need to undergo retesting for central confirmation of HER2 status.
- ✓ NOTE: DCIS components will not be counted in the determination of HER2 status
- ✓ ER/PR determination is required. ER and PR assays should be performed by immunohistochemical methods according to the local institution standard protocol.
- ✓ Bilateral breast cancers that individually meet eligibility criteria are allowed.
You may not qualify if…
- ✕ Any of the following due to teratogenic potential of the study drugs:
- ✕ Pregnant women
- ✕ Nursing women
- ✕ Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDs, surgical sterilization, abstinence, etc.).
- ✕ Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc.).
- ✕ Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)
- ✕ Patients with a history of previous invasive breast cancer.
- ✕ History of prior chemotherapy in the past 5 years.
Where it's recruiting
San Francisco
Derby · Fairfield · Glastonbury · Greenwich …
Miami · Plantation
Chicago
Carmel · Indianapolis
Brewer · Scarborough
Boston · Brighton · Burlington · Danvers …
Concord · Londonderry · Manchester · Portsmouth
Brooklyn · Mineola · New York
Durham · Raleigh
Columbus
Philadelphia · Pittsburgh
Source: ClinicalTrials.gov · NCT04893109 · last updated 2026-08-19